Key Highlights
- Alterity Therapeutics shares traded at $0.24, down 9.43%, during the 27 October 2026 trading session.
- The FY26 net loss was $23.40 million, up 92.6% from $12.15 million.
- Cash was $37.32 million at 30 June 2026, against $33.16 million a year earlier.
Shares in Alterity Therapeutics Ltd (ASX:ATH) were trading at $0.24, down 9.43%, during the 27 October 2026 trading session, while the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Alterity Therapeutics is an ASX-listed biotechnology company developing disease-modifying treatments for neurodegenerative disease. The company’s most recent document in the materials reviewed is its audited Appendix 4E for the year ended 30 June 2026.
FY26 Results (Appendix 4E)
The audited Appendix 4E reported Revenue of $1,716,656, up 284.7%, which is interest received on bank accounts, and a net loss after tax of $23,400,949, up 92.6% from $12,147,828. Cash was $37,317,962 at 30 June 2026, against $33,158,642 a year earlier.
Net Tangible Asset backing was 19.56 cents per share against 22.94 cents. No Dividend was paid or declared.
Reporting Structure
The principal activities were development of disease-modifying treatments for neurodegenerative disease, with no change during the year. The directors’ report is contained in the company’s Annual Report on Form 20-F, which includes the operating and financial review and risk factors. The company has US and UK subsidiaries.
Sector Context
The broader market was higher during the session, with the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Biotechnology and specialty pharmaceutical companies report progress through regulatory meetings, clinical studies, licensing and Capital raisings.
Alterity Therapeutics shares were trading at $0.24, down 9.43%, against a benchmark gain of 0.49%, a gap of 9.92 percentage points. The figures are session data recorded while the market was open and can change before the market finishes trading.
Risks
The loss widened by more than 90% and net tangible assets per share declined. The company has no Operating Revenue other than interest.
What Lies Ahead
The Appendix 4E points to the Form 20-F annual report for the review of operations, prospects, events since year end and risk factors.
Final Takeaway
Alterity shares fell during the session. The latest report shows a larger loss and a higher year-end cash balance.






Please wait processing your request...